Metabolic disease companies develop therapies, diagnostics and research technologies for disorders affecting how the body processes and stores energy. Their work spans diabetes, obesity, fatty liver disease and inherited metabolic conditions.
This category includes companies working on:
Browse 53 UK metabolic disease companies below.
Global diabetes and cardiometabolic medicines leader
Novo Nordisk Limited is the UK commercial and medical affiliate of Novo Nordisk A/S, the Danish pharmaceutical company focused on diabetes, obesity, and cardiometabolic disease. The UK operation covers commercialisation, medical affairs, and clinical trial activities. Separately, Novo Nordisk Research Centre Oxford…
Diagnostics, devices and diabetes care for global healthcare
Abbott Laboratories is a multinational healthcare company providing diagnostic instruments, reagents, and medical devices to hospitals, laboratories, and healthcare professionals. UK operations span commercial, R&D, and manufacturing functions across multiple sites. Core life science offerings include in vitro…
Novel peptide therapeutics targeting obesity and type 2 diabetes
Dia Beta Labs is a preclinical-stage biotechnology company developing first-in-class therapeutic peptides for metabolic disease. Spun out of the Diabetes Research Group at Ulster University, the company is advancing three peptide candidates that act on hormone receptors to preserve insulin-producing pancreatic…
Antigenic immunomodulation therapies targeting autoimmune disease
Phaim Pharma is a biotech company developing disease-modifying therapeutics for autoimmune conditions using its proprietary platform. The platform is designed to reset the immune system by reintroducing disease-specific antigenic epitopes, suppressing the autoaggressive T cell responses that underlie conditions such…
AI-powered RNAi drug discovery company developing hepatic medicines
Tangram Therapeutics is a biotechnology company combining artificial intelligence and RNA interference to discover and develop novel medicines. Its proprietary chemistry platform silences disease-driving genes in hepatocytes, and its AI platform drives target identification and siRNA design. The pipeline includes…
Human iPSC models and AI phenomics for drug discovery
Pixl Bio combines human induced pluripotent stem cell (iPSC) models with AI-driven image analysis for drug discovery and safety research. Its portfolio includes liver cells, stellate cells and disease models, alongside CRISPR engineering, high-content Cell Painting and contract studies. These tools help researchers…
Rapid diagnostic test kits for clinical, pharmacy and consumer markets
CIGA Healthcare is an ISO 13485-certified manufacturer of rapid lateral flow diagnostic tests and immunoassay products, supplying pharmacy outlets, health services and retailers across more than 70 countries. Its brand covers point-of-care and over-the-counter tests for pregnancy, infectious disease, cardiac…
Hydrogel capsule platform for weight loss and oral drug delivery
Oxford Medical Products is developing a gastroretentive hydrogel platform with two applications. The technology is a swallowable dual-polymer capsule that expands in the stomach to suppress appetite without pharmacological intervention; a Phase 2a clinical trial is underway following positive Phase 1 results. Oxford…
AI-powered stain-free digital pathology for liver fibrosis quantification
HistoIndex is a contract digital pathology organisation providing quantitative histology services for clinical trials and diagnostics, with a primary focus on liver fibrosis in metabolic liver disease. Its platform combines stain-free microscopy with artificial intelligence to generate objective, reproducible fibrosis…
GPCR-targeted small molecule therapeutics
Liminal BioSciences is a development-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate G protein-coupled receptor pathways. The company targets metabolic, inflammatory, and fibrotic diseases using an integrated drug discovery platform combining…
Synthetic chemical receptor R&D for implantable glucose biosensors
Lifecare Chemistry Ltd is a UK R&D subsidiary of Norwegian medical sensor company Lifecare ASA, established to develop and own proprietary analyte-specific synthetic receptors for use in Lifecare's implantable continuous glucose monitoring technology. Working in collaboration with researchers at the University of…
Clinical-stage biopharma targeting cancer immunotherapy and obesity
Poolbeg Pharma is a clinical-stage biopharmaceutical company developing small molecule therapies for high unmet medical needs. Its lead programme, POLB 001, is a p38 MAP kinase inhibitor in clinical trials for prevention of cytokine release syndrome associated with CAR-T and bispecific antibody cancer immunotherapies.…
Engineered therapeutic red blood cells for rare metabolic and other diseases
Scarlet Therapeutics is a biotechnology company developing a platform for generating therapeutic red blood cells (tRBCs). Erythroid cell lines are genetically engineered to produce red blood cells carrying high concentrations of therapeutic proteins, exploiting their natural tissue distribution, 120-day circulating…
Specialty biopharma covering oncology, neurology, and fertility
Merck Serono Limited is the UK commercial subsidiary of Merck KGaA's Healthcare division, a German science and technology company founded in 1668. The UK operation markets prescription medicines across oncology, neurology, immunology, endocrinology, and fertility. Key products include Erbitux for colorectal and…
Specialist renal pharmaceuticals and clinical nutrition products
Stanningley Pharma is a specialty pharmaceutical company focused on products for patients with chronic kidney disease and other hospital medicine therapeutic areas. The company licenses, develops, and markets prescription medicines and Foods for Special Medical Purposes into the NHS, including a calcium acetate…
AI-driven precision therapeutics for metabolic syndrome diseases
Multiomic Health is a data-centric therapeutics company developing precision medicines for metabolic syndrome-related conditions, including type 2 diabetes, cardiovascular disease, chronic kidney disease and non-alcoholic fatty liver disease. The company integrates multi-omics data with longitudinal clinical datasets…
Clinical-stage biopharma developing treatments for cancer and rare diseases
Biodexa Pharmaceuticals is a Cardiff-based clinical-stage biopharmaceutical company advancing a pipeline of proprietary drug formulations for diseases with high unmet need. Its lead programme, eRapa, an encapsulated oral formulation of rapamycin, is in a Phase 3 registrational trial for familial adenomatous polyposis,…
Reprogrammed stem cell therapies for vascular disease and chronic wounds
ReproGo is a Belfast-based regenerative medicine company developing Advanced Therapy Medicinal Products through direct cell reprogramming of adult cells into vascular lineages. The company's manufacturing approach produces stem cell-derived vascular cells and organoids through a xeno-free, low-dose process designed…
AI-enabled personalised dosing for drug-digital combination therapies
Closed Loop Medicine develops combination products integrating pharmaceutical therapies with AI-powered digital companions to personalise drug dosing for chronic conditions. Its platform applies pharmacometric modelling and patient response data to optimise treatment regimens. The pipeline includes co-packaged drug…
Biotech venture builder co-creating and scaling drug discovery companies
Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation. UK operations are based at Milton Park, Abingdon, with a further…